Company: Glycadia Inc.
Job title: Scientific Advisory Board
Addressing the Role of Glycated Albumin Non-Enzymatic Glycation in Retinal Vascular Diseases: GLY-230 2:15 pm
Compelling preclinical evidence of reversal of diabetic retinal vascular disease pathologies Sharing a reversal in abnormal biomarkers (including VEGF) with a small molecule given orally and/or with multimodal administration possibilities GLY-230 reverses in the documented direct pathogenic actions of geographic atrophy and decreases in generation of AGEs which are also pathogenic in RVDRead more
day: Day One